Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

2.

Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.

Yen YH, Lu SN, Chen CH, Wang JH, Wu CM, Hung CH, Tseng PL, Hu TH, Changchien CS, Lee CM.

Liver Int. 2007 Dec;27(10):1349-55.

PMID:
18036099
3.

Stopping lamivudine therapy after biochemical breakthrough may be a feasible option in selected HBeAg-positive patients.

Jang JW, Choi JY, Bae SH, Yoon SK, Kim CW, Nam SW, Lee CD, Lee YS, Cha SB, Chung KW.

J Med Virol. 2005 Nov;77(3):367-73.

PMID:
16173025
4.
5.
6.

The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation.

França PH, Coelho HS, Brandão CE, Segadas JA, Quintaes RF, Carrilho FJ, Ono-Nita S, Mattos AA, Tovo C, Gouvea VS, Sablon E, Vanderborght BO.

Braz J Med Biol Res. 2007 Dec;40(12):1605-14. Epub 2007 Oct 29.

7.

Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.

Sun J, Wang Z, Ma S, Zeng G, Zhou Z, Luo K, Hou J.

J Med Virol. 2005 Mar;75(3):391-8.

PMID:
15648063
8.
9.

Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.

Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.

J Med Virol. 2005 Apr;75(4):491-8.

PMID:
15714490
10.

The effectiveness of lamivudine treatment in cirrhotic patients with HBV precore mutations: a prospective, open-label study.

Bolukbas C, Bolukbas FF, Kendir T, Akbayir N, Ince AT, Abut E, Horoz M, Dalay AR, Sokmen MH, Ovunc O.

Dig Dis Sci. 2006 Jul;51(7):1196-202.

PMID:
16944009
11.

Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.

Kazim SN, Chauhan R, Das BC, Sarin SK.

J Gastroenterol Hepatol. 2006 Oct;21(10):1525-32.

PMID:
16928212
12.

Factors influencing outcome of lamivudine in anti-HBe-positive chronic hepatitis B.

Ascione A, Ascione T, Lanza AG, Utech W, Di Costanzo GG, Macri M.

Hepatogastroenterology. 2006 Nov-Dec;53(72):919-23.

PMID:
17153453
13.

Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B.

Thabut D, Thibault V, Bernard-Chabert B, Mouquet C, Di Martino V, Le Calvez S, Opolon P, Benhamou Y, Bitker MO, Poynard T.

Eur J Gastroenterol Hepatol. 2004 Nov;16(12):1367-73.

PMID:
15618847
14.

Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.

Wong VW, Wong GL, Tsang SW, Hui AY, Chim AM, Yiu KK, Chan HY, Chan FK, Sung JJ, Chan HL.

Antivir Ther. 2008;13(4):571-9.

PMID:
18672536
15.
16.

Viral features of lamivudine resistant hepatitis B genotypes A and D.

Zöllner B, Petersen J, Puchhammer-Stöckl E, Kletzmayr J, Sterneck M, Fischer L, Schröter M, Laufs R, Feucht HH.

Hepatology. 2004 Jan;39(1):42-50.

PMID:
14752821
17.

Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.

Marrone A, Zampino R, Karayannis P, Cirillo G, Cesaro G, Guerrera B, Ricciotti R, del Giudice EM, Utili R, Adinolfi LE, Ruggiero G.

Aliment Pharmacol Ther. 2005 Oct 15;22(8):707-14.

18.

[Long-term clevudine therapy in nucleos(t)ide-naïve and lamivudine-experienced patients with hepatitis B virus-related chronic liver diseases].

Lee HJ, Eun JR, Lee CH, Hwang JS, Suh JI, Kim BS, Jang BK.

Korean J Hepatol. 2009 Jun;15(2):179-92. doi: 10.3350/kjhep.2009.15.2.179. Korean.

19.

Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.

Tsubota A, Arase Y, Suzuki F, Kobayashi M, Matsuda M, Sato J, Suzuki Y, Akuta N, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H.

J Med Virol. 2004 May;73(1):7-12.

PMID:
15042641
20.

Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B.

Tsubota A, Arase Y, Suzuki Y, Suzuki F, Sezaki H, Hosaka T, Akuta N, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H.

J Gastroenterol Hepatol. 2005 Mar;20(3):426-32.

PMID:
15740488
Items per page

Supplemental Content

Write to the Help Desk